The efficacy and safety of mesalazine in the treatment o f inflammatory bowel disease--A nationwide multicenter clinical trial
WU Guo-liang
TANG Ye-qiu
SU Xiang-xi
HU Fu-Lian
LIN Geng-jin
YUAN Ai-li
XIE Peng-yan
LIU Jian-xiang
YUAN Yao-zong
HU Yun-biao
XU Guo-ming
ZHANG Xiao-j in
YANG Zhao-xu
ZHAO Ying-heng
YANG Jian－quan
ZHOU Lan
Abstract：Objective:To observe the efficacy and safety of Etiasa,a control released tablet of mesalazine,in treatment of inflammatory bowel diseas e(IBD) in comparison with salicylazosulfapyridine (SASP).Methods:The r andomized,multicenter,and controlled study was conducted in 89 patients with end oscopy confirmed mild or moderate ulcerative colitis (UC) or Crohn's disease (CD ) of initial onset.They were randomly allocated to Etiasa (n=52) or SASP(n =37)both in a dose of 1.0g qid for 6 weeks.After that they were examined b y endoscopy.The efficacy and side effects were evaluated at week 4 and week 6. Results:There were 3 patients in SASP withdrawn from the study because of al lergic reaction or leukopenia at the end of the 4th week.52 patients in Etiasa g roup and 34 patients in SASP group completed the study.The obvious improvement r ate in Etiasa group at the end of the 4th and the 6th week is 52.0% and 71.2% re spectively,by evaluation of patients vs 20.6% and 50.0% in SASP group (P<0.0 5).Disappearance rate of GI symptoms at the end of the 6th week is 57.7% in Etia sa group vs 50.0% in SASP group(P<0.05).Cure rate confirmed by endoscopy at the end of the 6th week is 26.9% in Etiasa group vs 2.9% in SASP group (P <0.05).The incidence of side effects is 1.9%(1/52) in Etiasa group vs 10.8%.(4 /37) in SASP group(P>0.05)。Conclusion:Etiasa is an effective agen t for treatment of IBD.
Machine-generated Keywords：
Publication Date：2001-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 201-204 )